May 17, 2022 / 06:35PM GMT
Luca Issi - RBC Capital Markets - Analyst
Thanks. Hello, everybody. Luca Issi, Senior Biotech Analyst here at RBC Capital Market.
And today, it's our great privilege to have Beam Therapeutics with us for a fireside chat. Representing the company, we have John Evans, Chief Executive Officer.
John, thanks so much for joining us. How are you doing today?
John Evans - Beam Therapeutics Inc. - CEO & Board Member
Great. Great to be here. Thanks for having me.
Luca Issi - RBC Capital Markets - Analyst
Good, good.
So we have a long list of questions here, but actually, maybe before we start asking you about the individual program, would be great if you can just talk about some of the progress that the organization has made over the last few months, and most importantly, what's ahead here for Beam?
John Evans - Beam Therapeutics Inc. - CEO & Board Member
Sounds good. So yes, Beam, of course, is working on next-generation gene editing tools,
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers